Table 2.
The genotypes frequency of all 16 studied variants in stroke cases and control subjects
| Gene and variants | Controls (n = 1,263) | Stroke cases | ||||
|---|---|---|---|---|---|---|
| Total cases (n = 1,405) | Hemorrhagic stroke (n = 383) | Atherothrombotic stroke (n = 607) | Lacunar infarction (n = 415) | |||
| APOA1 PNTR | ||||||
| LRN | 125 (9.9%) | 1709 (12.1%) | 48 (12.5%) | 73 (12.0%) | 49 (11.8%) | |
| HRN | 1,138 (90.1%) | 1,235 (87.9%) | 335 (87.5%) | 534 (88.0%) | 366 (88.2%) | |
| MTHFR rs1801133 | ||||||
| CC | 410 (32.5%) | 412 (29.3%) | 116 (30.3%) | 173 (28.5%) | 123 (29.6%) | |
| CT | 585 (46.3%) | 664 (47.3%) | 182 (47.5%) | 287 (47.3%) | 195 (47.0%) | |
| TT | 268 (21.2%) | 329 (23.4%) | 85 (22.2%) | 147 (24.2%) | 97 (23.4%) | |
| VKORC1 rs2359612 | ||||||
| TT | 1,099 (87.0%) | 1,129 (80.4%) | 314 (82.0%) | 496 (81.7%) | 319 (76.9%) | |
| TC | 156 (12.4%) | 259 (18.4%) | 62 (16.2%) | 107 (17.6%) | 90 (21.7%) | |
| CC | 8 (0.6%) | 17 (1.2%) | 7 (1.8%) | 4 (0.7%) | 6 (1.4%) | |
| ALOX5AP rs4769874 | ||||||
| GG | 1,162 (92.0%) | 1,277 (90.9%) | 350 (91.4%) | 551 (90.8%) | 376 (90.6%) | |
| GA | 96 (7.6%) | 122 (8.7%) | 32 (8.4%) | 52 (8.6%) | 38 (9.2%) | |
| AA | 5 (0.4%) | 6 (0.4%) | 1 (0.3%) | 4 (0.7%) | 1 (0.2%) | |
| ALOX5AP rs10507391 | ||||||
| TT | 635 (50.3%) | 703 (50.0%) | 205 (53.5%) | 283 (46.6%) | 215 (51.8%) | |
| TA | 505 (40.0%) | 568 (40.4%) | 145 (37.9%) | 257 (42.3%) | 166 (40.0%) | |
| AA | 123 (9.7%) | 134 (9.5%) | 33 (8.6%) | 67 (11.0%) | 34 (8.2%) | |
| NOTCH3 rs1043994 | ||||||
| GG | 1,027 (81.3%) | 1,169 (83.2%) | 317 (82.8%) | 502 (82.7%) | 350 (84.3%) | |
| GA | 218 (17.3%) | 211 (15.0%) | 62 (16.2%) | 94 (15.5%) | 55 (13.3%) | |
| AA | 18 (1.4%) | 25 (1.8%) | 4 (1.0%) | 11 (1.8%) | 10 (2.4%) | |
| VEGFA rs2010963 | ||||||
| GG | 386 (30.6%) | 436 (31.0%) | 135 (35.2%) | 190 (31.3%) | 111 (26.7%) | |
| GC | 619 (49.0%) | 684 (48.7%) | 179 (46.7%) | 288 (47.4%) | 217 (52.3%) | |
| CC | 258 (20.4%) | 285 (20.3%) | 69 (18.0%) | 129 (21.3%) | 87 (21.0%) | |
| VEGFA rs1570360 | ||||||
| GG | 357 (28.3%) | 401 (28.5%) | 123 (32.1%) | 166 (27.3%) | 112 (27.0%) | |
| GA | 628 (49.7%) | 709 (50.5%) | 184 (48.0%) | 300 (49.4%) | 225 (54.2%) | |
| AA | 278 (22.0%) | 295 (21.0%) | 76 (19.8%) | 141 (23.2%) | 78 (18.8%) | |
| VEGFA rs833061 | ||||||
| TT | 561 (44.4%) | 616 (43.8%) | 156 (40.7%) | 266 (43.8%) | 194 (46.7%) | |
| TC | 566 (44.8%) | 628 (44.7%) | 176 (46.0%) | 273 (45.0%) | 179 (43.1%) | |
| CC | 136 (10.8%) | 161 (11.5%) | 51 (13.3%) | 68 (11.2%) | 42 (10.1%) | |
| KDR rs2071559 | ||||||
| TT | 624 (49.4%) | 713 (50.7%) | 168 (43.9%) | 342 (56.3%) | 203 (48.9%) | |
| TC | 505 (40.0%) | 567 (40.4%) | 175 (45.7%) | 219 (36.1%) | 173 (41.7%) | |
| CC | 134 (10.6%) | 125 (8.9%) | 40 (10.4%) | 46 (7.6%) | 39 (9.4%) | |
| KDR rs1870377 | ||||||
| AA | 473 (37.5%) | 519 (36.9%) | 115 (30.0%) | 249 (41.0%) | 155 (37.3%) | |
| AT | 573 (45.4%) | 632 (45.0%) | 192 (50.1%) | 254 (41.8%) | 186 (44.8%) | |
| TT | 217 (17.2%) | 254 (18.1%) | 76 (19.8%) | 104 (17.1%) | 74 (17.8%) | |
| Chr.9p21.3 rs2383206 | ||||||
| AA | 390 (30.9%) | 417 (29.7%) | 106 (27.7%) | 170 (28.0%) | 141 (34.0%) | |
| AG | 631 (50.0%) | 674 (48.0%) | 187 (48.8%) | 289 (47.6%) | 198 (47.7%) | |
| GG | 242 (19.2%) | 314 (22.3%) | 90 (23.5%) | 148 (24.4%) | 76 (18.3%) | |
| Chr.9p21.3 rs2383207 | ||||||
| AA | 171 (13.5%) | 192 (13.7%) | 59 (15.4%) | 72 (11.9%) | 61 (14.7%) | |
| AG | 591 (46.8%) | 629 (44.8%) | 155 (40.5%) | 280 (46.1%) | 194 (46.7%) | |
| GG | 501 (39.7%) | 584 (41.6%) | 169 (44.1%) | 255 (42.0%) | 160 (38.6%) | |
| Chr.9p21.3 rs10757278 | ||||||
| AA | 303 (24.0%) | 312 (22.2%) | 75 (19.6%) | 132 (21.7%) | 105 (25.3%) | |
| AG | 633 (50.1%) | 658 (46.8%) | 184 (48.0%) | 274 (45.1%) | 200 (48.2%) | |
| GG | 327 (25.9%) | 435 (31.0%) | 124 (32.4%) | 201 (33.1%) | 110 (26.5%) | |
| Chr.9p21.3 rs10757274 | ||||||
| AA | 364 (28.8%) | 378 (26.8%) | 89 (23.2%) | 158 (26.0%) | 131 (31.6%) | |
| AG | 642 (50.8%) | 667 (47.5%) | 186 (48.6%) | 284 (46.8%) | 197 (47.5%) | |
| GG | 257 (20.3%) | 360 (25.6%) | 108 (28.2%) | 165 (27.2%) | 87 (21.0%) | |
Abbreviations: ALOX5AP, arachidonate 5‐lipoxygenase‐activating protein; APOA1, apolipoprotein (a); Chr.9p21.3, Chromosome 9p21.3; HRN, high repeat number (sum of both alleles ≥16); KDR, kinase insert domain‐containing receptor; LRN, low repeat number (sum of both alleles <16); MTHFR, methylenetetrahydrofolate reductase; PNTR, a pentanucleotide TTTTA repeat; VEGFA, vascular endothelial growth factor; VKORC1, vitamin K epoxide reductase complex subunit 1.